Uses

Pasireotide is a somatostatin analogue indicated for the treatment of adult patients with Cushing's disease for whom pituitary surgery is not an option or has not been curative. It reduces cortisol production by suppressing ACTH secretion.

Do not use if

No absolute contraindications listed in the FDA label. Use with caution in patients with diabetes, cardiac disease, or hepatic impairment.

Side effects

Common adverse effects include hyperglycemia and diabetes mellitus, diarrhea, nausea, cholelithiasis, and injection-site reactions. Bradycardia and QT interval prolongation may occur. Hypocortisolism is a pharmacodynamic consequence of effective therapy.

Warnings

Hyperglycemia requiring antidiabetic therapy may develop. Bradycardia and QT prolongation warrant cardiac monitoring. Liver enzymes should be monitored periodically. Hypocortisolism may necessitate glucocorticoid replacement.

How it works

Pasireotide is a cyclohexapeptide somatostatin analogue with high affinity for somatostatin receptor subtypes 1, 2, 3, and 5. It suppresses ACTH secretion from corticotroph tumors, thereby reducing cortisol production from the adrenal glands.

Storage

Store at controlled room temperature. Refer to manufacturer packaging for specific storage conditions for each concentration.